Who
Bruce N. Jacobs
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Kymera Therapeutics.
In numbers
- Trades disclosed
- 121
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $28.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Aug 2020
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $327K61,378 at $5.33 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —61,378 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $166K1,500 at $110.54 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $190K1,700 at $111.57 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —61,378 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $124K1,100 at $112.79 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $469K4,110 at $114.19 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.9M51,375 at $114.77 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $923K7,971 at $115.82 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $720K6,153 at $116.99 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $377K3,200 at $117.70 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Code M | $327K61,378 at $5.33 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $166K1,500 at $110.54 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $190K1,700 at $111.57 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $124K1,100 at $112.79 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $469K4,110 at $114.19 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $5.9M51,375 at $114.77 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $923K7,971 at $115.82 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $720K6,153 at $116.99 | filing |
| 30 Jun 2026filed 2 Jul 2026 | KYMR Kymera TherapeuticsBiotechnology | SEC FORM 4 Sold | $377K3,200 at $117.70 | filing |
News
Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)KYMR · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Bruce N. Jacobs; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.